Scientific Program

Conference Series Ltd invites all the participants across the globe to attend World Cardiology and Cardiologist Meeting Quality Hotel Globe Stockholm, Sweden.

Submit your Abstract
or e-mail to

events@conferenceseries.com
cardiologymeeting@cardiologyconference.org
cardiologymeeting@cardiologyconference.org

Scientific Program Day 1
Scientific Program Day 2

Day 2 :

Keynote Forum

Mikhail Y Rudenko

Russian New University, Russia

Keynote: Cardiometry : A new fundamental scientific field in cardiology
Conference Series Cardiology Meet 2018 International Conference Keynote Speaker Mikhail Y Rudenko photo
Biography:

Rudenko M Yu has been engaged in research in the field of Physiology and Medicine, as well as Medical Equipment Engineering since 1979. From 1980 to 1989, he was engaged in Space Medicine. He has supervised the development of methods and instruments for detecting the psycho-physiological state of spacecraft human operators. In 1990, he has established a private educational institution “The Institute of Chinese medicine”, till 1998, 17 professors of traditional Chinese medicine (TCM) from China worked in this institute. He has excellently mastered the theory and practice of TCM. He wrote several books on TCM and eastern philosophy. He has created an educational course for western doctors. In 1991, he took an active part in foundation of a private educational institution “Russian New University “in Moscow and currently 25000 students study there. At the university, he headed the Scientific School of Hemodynamic Studies of Cardiovascular System. In the process of his research 9 laws of physiology were revealed. He is a member of ESC W.G. on e-cardiology, ID439666. He takes active part in the W.G. conferences and meetings.

 

Abstract:

Aim: The aim of the present study is to expand diagnostics capabilities in Cardiology using the new theory of cardiometry.
 
Materials & Methods: Non-invasive measurement of blood volumes in each cardiac cycle and parameters of cardiac muscle metabolism upon digital processing of an ECG alone allows monitoring of any changes in the cardiovascular system performance. No additional examination is required. The procedure takes only 20 seconds.
 
Conclusions: Using the theory of cardiometry in practice allows you: (1) to determine heart life expectancy in an individual with an accuracy up to several hours; (2) to evaluate efficacy of the selected medication and (3) to effectively use the method in
sports.

Keynote Forum

Samer Ellahham

Cleveland Clinic, United Arab Emirates

Keynote: Heart failure in hemodialysis patients 2018
Biography:

Samer Ellahham has served as Chief Quality Officer and Global Healthcare Leader for SKMC since 2009. He is a Board-certified Internist, Cardiologist and Vascular Medicine Senior Consultant and continues to care for patients. He received his Undergraduate Degree in Biology and his MD from the American University of Beirut,
Beirut, Lebanon. He has obtained his fellowship in Cardiology at the Medical College of Virginia (MCV) in USA. He has worked in Washington DC in several clinical and leadership positions before moving to UAE in 2008. He led the First AHA GWTG Heart Failure Initiative outside US and was the recipient of the AHA GWTG Award in Washington, DC. He is the champion of the AHA GWTG in the region. He continues to be an active Clinician. He is board certified in internal medicine, vascular medicine, Cardiology and quality. He was recently recertified in 2017 by the American Board of Cardiology (ABIM). He is a Fellow of the American College of Cardiology and key member in Heart Failure and Transplant, Adult Congenital and Pediatric Cardiology, Cardio-oncology and
Peripheral Vascular Disease sections.

Abstract:

Patients with end-stage renal disease requiring dialysis are at increased risk for development of heart failure (HF). Factors that may contribute to HF in the dialysis patient include fluid overload, left ventricular diastolic dysfunction, LV systolic dysfunction,
and valvular heart disease. A high-output state caused by shunting through hemodialysis arteriovenous access can also precipitate HF.
 
A proposed functional classification scheme was developed specifically for patients with end-stage renal disease (ESRD) by the Acute Dialysis Quality Initiative (ADQI) XI Workgroup. The cardiac evaluation of dialysis patients should address whether HF is present, what type of HF is present (HFrEF; LVEF ≤40 percent, HF with midrange ejection fraction HFmrEF; LVEF 41 to 50 percent, HF
with preserved ejection fraction HFpEF; LVEF >50 percent, HF from valve disease, and identification of contributing factors. The approach to management of HF in the dialysis patient varies depending on the clinical presentation.

  • Cardiovascular Disease | Heart Disease & Failure | Angiography & Interventional Cardiology | Cardiac Nursing | Heart Diagnosis | Cardiac Surgery | Cardiovascular Disease | Cardio-Oncology
Location: Pluto
Speaker

Chair

Ovidio Alberto Garcia Villarreal

Hospital Zambrano-Hellion, Mexico

Speaker

Co-Chair

Mikhail Y Rudenko

Russian New University, Russia

Session Introduction

Ovidio Alberto Garcia Villarreal

Hospital Zambrano-Hellion, Mexico

Title: Mitraclip therapy: Rules do not change, Annuloplasty ring is a must
Speaker
Biography:

Ovidio A García Villarreal is the Founder and present President of the Mexican College of Cardiovascular and Thoracic Surgery. He is the immediate past President of the Mexican Society of Cardiac Surgery. He is a Cardiac Surgeon retired from the social medicine, now focused exclusively on private practice in Monterrey, México.

He is member of the Mexican Society of Cardiac Surgery, Mexican College of Cardiovascular and Thoracic Surgery, Society of Thoracic Surgeons, European Association of Cardiothoracic Surgery, and of the National Association of Cardiologists of Mexico. He has published more than 50 articles indexed in PubMed, and many others in non-indexed journals. He is the Founder and present Editor-in-Chief of Cirugía Cardiaca en México, official journal of the Mexican Society of Cardiac Surgery since 2015. He is Reviewer in many prestigious international journals, as Annals of Thoracic Surgery, European Journal of Cardio-thoracic Surgery, Arch. Cardiol. Mex., and many other open access journals. He is the Precursor and the highest extensive experienced in the field of atrial fibrillation surgery (maze procedure), mitral valve repair, and aortic valve sparing-operations (David procedure, Yacoub procedure) in México. He was awarded with the National Prize in Surgery 2000 “Fernando Montes de Oca” from the Mexican Academy of Surgery, the highest prize for surgery in México.

 

 

Abstract:

Mitral regurgitation (MR) can be addressed by means of “French Correction” principles described by Carpentier. Remodelling on a frame plays a central role in this strategy. The annuloplasty ring forces leaflet coaptation, distributes evenly all the tensional forces in the repair. Moreover, it avoids any further annulus dilation. It has been demonstrated that the lack of the annuloplasty ring is one of the most powerful predictors for failure after MVR (mitral valve repair). Edge-to-Edge technique is the basis of the MitraClip therapy. Hence, it is not the exception to this rule. Several studies have made very clear that, in this context, the longer the follow-up, the higher the recurrence of the MR after MVR. This is especially true after 10 years follow-up. With this framework, the fact that constantly calls our attention is why the annuloplasty ring is not taken into consideration at the moment to install the MitraClip device. Rules do not become different depending on a given specific surgical or percutaneous approach. The answer has become more than evident by the surgical group. When analyzing the trials concerning the MitraClip, follow-ups are not long enough in order to get strong conclusions about ringles MitraClip.

EVEREST-II trial is a 5-year follow-up. However, the achieved results could not be reproduced by others. Current indication based on the current approval device in USA is exclusively on the primary/degenerative MR patients with high-risk for operation with no adequate response to optimal medical therapy. The main indication in Europe for MitraClip is functional MR; in USA as well as Europe, current indication for this kind of procedure is IIb, level of recommendation B or C, respectively. COAPT trial has been designed to test the MitraClip usefulness in functional MR. Results are still on the way. Nevertheless, rules do not change at all. Restrictive annuloplasty is the most common technique to address the functional MR. Even though there is an overoptimistic belief about MitraClip all alone could be sufficient in order to treat MR; everything seems to indicate just the opposite. Annuloplasty with a ring is an absolute must. Cardioband or Millipede IRIS can offer some solution to cope with all these shortcomings

Nikolaos Bourmpoulis

Red Cross Hospital Athens, Greece

Title: Paradoxical embolism PFO: Easy to occlude; Effective?
Biography:

Nikolaos Bourmpoulis is the Director of Catheterization Laboratory in the Department of Interventional Cardiology, Korgialenio - Benakio Red Cross Hospital Athens, Greece.

 

Abstract:

Patent foramen ovale (PFO) has been considered as the main cause of paradoxical embolism in the absence of open communication between left and right circulation. On the other hand, PFO itself, with its slow flow between the atrial septum primum and secundum can form thrombus which potentially can be the source of emboli to systematic circulation. Three randomized, open label trials, Gore REDUCE (closure device versus antiplatelet therapy alone compared to the combination of both), CLOSE (closure devise or anticoagulants versus antiplatelet therapy to prevent recurrence of stroke), and RESPECT (closure device versus standard treatment) showed that the risk of stroke was lower with patent foramen ovale closure than with medical treatment alone.

Despite the speculations for these trials and their limitations, it seems that in the near future the treatment of cryptogenic stroke is going to change, a fact that will be probably reflected to the guidelines. The more aggressive approach of interventional cardiologists will balance the more conservative approach of neurologists and will give new fields for investigation, answering questions as how urgently must we intervene after the first stroke to prevent subclinical strokes shown by MRI, or if there is field for primary prevention when a PFO is diagnosed before a paradoxical embolism.

 

Dolina Gencheva

Medical University of Plovdiv, Bulgaria

Title: Diffi culties in the treatment of a 12-old patient with familial hypercholesterolemia and the inclusion of a PCSK 9-inhibitor
Speaker
Biography:

Dolina Gencheva has completed her Graduation in Medicine in 2014 at Medical University, Plovdiv, Bulgaria and is currently specializing in the field of Cardiology at the University Hospital Sv. Georgi-Plovdiv. She is the first author of one article, published in a referenced medical journal, co-author of several other journals with impact factors.

Abstract:

The case report concerns a 12 year old boy with genetically diagnosed compound heterozygous form of familial hypercholesterolemia, who first presented with xanthomas on both knees and elbows and a family history of early coronary artery disease and sudden cardiac death. Before the initiation of lipid lowering treatment at the age of 11, the patient’s level of total and LDL cholesterol were 18 mmol/l and 15 mmol/l, respectively. Over the course of several months, the treatment with a statin and a cholesterol absorption inhibitor achieved a 50% decrease of LDL cholesterol level without reaching the absolute recommended target of 3.5 mmol/l. Additional tests of the boy showed initial fibro-degenerative changes of his mitral valve annulus and aortic valve, while his intima media thickness and cardio-pulmonary test were normal. Considering the high risk of early onset atherosclerosis and cardiovascular mortality as well as the unavailability of LDL-apheresis, the patient’s case was reviewed by a national committee, consisting of a cardiologist, a pediatrician and an endocrinologist and approved for adjuvant treatment with a PCSK 9-inhibitor with the consent of his parent.=

Samer Ellahham

Cleveland Clinic, United Arab Emirates

Title: Reducing Door to- Balloon time for acute ST elevation myocardial infarction in primary percutaneous intervention: The role of lean six sigma improvement
Biography:

Samer Ellahham has served as Chief Quality Officer and Global Healthcare Leader for SKMC since 2009. He is a Board-certified Internist, Cardiologist and Vascular Medicine Senior Consultant and continues to care for patients. He received his Undergraduate Degree in Biology and his MD from the American University of Beirut, Beirut, Lebanon. He has obtained his fellowship in Cardiology at the Medical College of Virginia (MCV) in USA. He has worked in Washington DC in several clinical and leadership positions before moving to UAE in 2008. He led the First AHA GWTG Heart Failure Initiative outside US and was the recipient of the AHA GWTG Award in Washington, DC.
 
He is the champion of the AHA GWTG in the region. He continues to be an active Clinician. He is board certified in internal medicine, vascular medicine, Cardiology and quality. He was recently recertified in 2017 by the American Board of Cardiology (ABIM). He is a Fellow of the American College of Cardiology and key member in Heart Failure and Transplant, Adult Congenital and Pediatric Cardiology, Cardio-oncology and Peripheral Vascular Disease sections.

Abstract:

 

Cardiovascular diseases are the leading causes of death in the UAE. Prompt reperfusion access is essential for patients who have myocardial infarction (MI) with ST-segment elevation as they are at relatively high risk of death. This risk may be reduced by primary percutaneous coronary intervention (PCI), but only if it is performed in timely manner.
 
Guidelines recommend that the interval between arrival at the hospital and intracoronary balloon inflation (door-to-balloon (D2B) time) during primary PCI should be 90 minutes or less. The earlier therapy is initiated, the better the outcome. Our aim was to decrease the door-to-balloon time for patients with ST segment elevation myocardial infarction (STEMI) who come through the emergency department (ED) in a tertiary hospital in UAE, to meet the standard of less than 90 minutes. A multidisciplinary team was formed including interventional Cardiologists, catheterization laboratory personnel, emergency
department caregivers and quality staff. The project utilized the Lean Six Sigma methodology which provided a powerful approach to quality improvement. The process minimized waste and variation, and a decreased median door-to-balloon time from 75.9 minutes to 60.1 minutes was noted. The percentage of patients who underwent PCI within 90 minutes increased from 73% to 96%. In conclusion, implementing the Lean Six Sigma
methodology resulted in having processes that are leaner, more efficient and minimally variable. While recent publication failed to provide evidence of better outcome, the lessons learned were extrapolated to other primary percutaneous coronary intervention centers in our system. This would have marked impact on patient safety, quality of care and patient experience.